Beta Bionics Q4 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy BBNX?
Source: seekingalpha
- Earnings Highlights: Beta Bionics reported a Q4 GAAP EPS of -$0.30, beating expectations by $0.10, with revenue of $32.1 million reflecting a 57% year-over-year growth, indicating strong market performance.
- Future Guidance: The company estimates total revenue for 2026 to be approximately $130 million to $135 million, with 36% to 38% of new patient starts expected to be reimbursed through the PBP channel, showcasing a proactive strategy for market share expansion.
- Operational Loss Analysis: The Q4 operational loss was $16.1 million, or 50% of sales, an improvement from $13.0 million or 64% of sales in Q4 2024, indicating enhanced operational efficiency.
- Cash Position: As of December 31, 2025, Beta Bionics reported $264.7 million in cash and cash equivalents, providing a solid financial foundation for future growth despite ongoing net losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBNX
Wall Street analysts forecast BBNX stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 13.020
Low
17.00
Averages
27.11
High
40.00
Current: 13.020
Low
17.00
Averages
27.11
High
40.00
About BBNX
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ranking of Small-Cap Stocks with Positive EPS Surprises
- Positive Earnings Surprises: Beta Bionics (BBNX) leads the list with a Quant Rating of 1.07, followed closely by Upstream Bio (UPB) and Ribbon Communications (RBBN), indicating a positive quarterly earnings performance among small-cap stocks.
- Quant Rating Implications: Despite these companies posting positive earnings surprises, all carry a 'Strong Sell' quantitative profile, suggesting a lack of market confidence in their future performance, which may influence investor decisions.
- Rating System Overview: Seeking Alpha's Quant system ranks stocks based on critical metrics such as valuation, growth, stock momentum, and profitability, with ratings ranging from 1 to 5, where scores above 3.5 indicate bullish sentiment and scores of 2.5 or below represent bearish outlooks.
- Small-Cap ETF Landscape: Related small-cap ETFs include IJR, IWM, VB, VBR, VBK, SCHA, SPSM, and DFAS, providing investors with indirect exposure to the fluctuations in the small-cap market.
See More
Faruqi & Faruqi Investigates Beta Bionics After 37% Stock Plunge
- Stock Plunge: Beta Bionics' shares plummeted approximately 37% on January 9, 2026, primarily due to the company's expectation of fewer patient starts in Q4 than analysts estimated, raising significant investor concerns and fears.
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating whether Beta Bionics issued misleading statements or failed to disclose material information to investors, indicating a rising legal risk for the company that could lead to substantial investor losses.
- Investor Rights Protection: The firm encourages investors who suffered losses to contact securities litigation partner Josh Wilson directly, highlighting the firm's commitment to protecting investor rights and providing legal support for potential claims.
- Firm Background: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, which further enhances investor confidence in the ongoing investigation.
See More
Faruqi & Faruqi Investigates Investor Losses in Beta Bionics
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Beta Bionics, aiming to provide legal support for investors who have suffered significant losses, indicating possible legal liabilities for the company.
- Investor Rights Protection: The firm encourages investors who have incurred losses in Beta Bionics stock or options to contact partner Josh Wilson directly, demonstrating its commitment to safeguarding investor legal rights.
- Reputation Impact: As a national securities law firm founded in 1995 that has recovered hundreds of millions for investors, this investigation could affect Beta Bionics' market reputation and future financing capabilities.
- Legal Consultation Channels: Investors can reach out to Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information on their legal rights, highlighting the firm's emphasis on client service.
See More
Beta Bionics Under Investigation Amid Stock Plunge
- Investor Investigation: Pomerantz LLP is investigating on behalf of Beta Bionics investors regarding potential securities fraud or other unlawful business practices, highlighting serious concerns about the company's governance and transparency.
- Declining Financial Performance: Beta Bionics reported a 36% year-over-year increase in new patient starts for Q4 2026, significantly lower than the 68% increase in the previous quarter, indicating challenges in market expansion.
- Stock Price Plunge: Following the earnings report, Beta Bionics' stock price fell by $11.85, or 37.03%, closing at $20.15 per share on January 9, 2026, severely impacting investor confidence.
- Legal Context: Pomerantz LLP, a renowned securities class action law firm with over 85 years of experience, focuses on advocating for victims of securities fraud, suggesting that this case may lead to broader legal implications.
See More
Beta Bionics Q4 2025 Earnings Call Highlights
- Significant User Growth: In 2025, Beta Bionics added nearly 20,000 new users, doubling its total user base to over 35,000, which lays a solid foundation for future market expansion and user adoption.
- Strong Financial Performance: The company reported $100.3 million in net sales for 2025, representing a 54% year-over-year growth, with Q4 sales reaching $32.1 million, up 57%, demonstrating robust competitive strength in the market.
- Margin Improvement: Q4 gross margin reached 59%, a 179 basis point increase year-over-year, reflecting the success in the pharmacy channel and its positive impact on overall profitability.
- Optimistic Future Outlook: Management expects revenue in 2026 to range between $130 million and $135 million, with plans to expand the sales force into 20 new territories, showcasing confidence in sustained growth and strategic positioning.
See More
Beta Bionics Reports Q4 2025 Financial Results
- Improved Financial Performance: Beta Bionics reported a narrowed net loss of $13.47 million in Q4 2025, down from $18.11 million the previous year, indicating positive progress in cost management and revenue growth, although the full-year net loss widened to $73.20 million, highlighting ongoing concerns about long-term profitability.
- Significant Revenue Growth: The company achieved a 57% year-over-year revenue increase in Q4, reaching $32.12 million, primarily driven by a 295% surge in Pharmacy Benefit Plan channel sales to $9.8 million, which lays a solid foundation for future market expansion and product acceptance.
- Optimistic Future Outlook: Beta Bionics anticipates total revenue for 2026 to be between $130 million and $135 million, reflecting confidence in new patient starts, with an estimated 36% to 38% expected to be reimbursed through the Pharmacy Benefit Plan, indicating strong market demand potential.
- R&D Progress on Track: The company recently completed the first-in-human Phase 2a feasibility trial for its bihormonal system in New Zealand and plans to initiate an additional feasibility trial in the first half of 2026, preparing for advanced-stage development and enhancing its competitive edge in diabetes treatment.
See More
Ranking of Small-Cap Stocks with Positive EPS Surprises
- Positive Earnings Surprises: Beta Bionics (BBNX) leads the list with a Quant Rating of 1.07, followed closely by Upstream Bio (UPB) and Ribbon Communications (RBBN), indicating a positive quarterly earnings performance among small-cap stocks.
- Quant Rating Implications: Despite these companies posting positive earnings surprises, all carry a 'Strong Sell' quantitative profile, suggesting a lack of market confidence in their future performance, which may influence investor decisions.
- Rating System Overview: Seeking Alpha's Quant system ranks stocks based on critical metrics such as valuation, growth, stock momentum, and profitability, with ratings ranging from 1 to 5, where scores above 3.5 indicate bullish sentiment and scores of 2.5 or below represent bearish outlooks.
- Small-Cap ETF Landscape: Related small-cap ETFs include IJR, IWM, VB, VBR, VBK, SCHA, SPSM, and DFAS, providing investors with indirect exposure to the fluctuations in the small-cap market.
See More
Faruqi & Faruqi Investigates Beta Bionics After 37% Stock Plunge
- Stock Plunge: Beta Bionics' shares plummeted approximately 37% on January 9, 2026, primarily due to the company's expectation of fewer patient starts in Q4 than analysts estimated, raising significant investor concerns and fears.
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating whether Beta Bionics issued misleading statements or failed to disclose material information to investors, indicating a rising legal risk for the company that could lead to substantial investor losses.
- Investor Rights Protection: The firm encourages investors who suffered losses to contact securities litigation partner Josh Wilson directly, highlighting the firm's commitment to protecting investor rights and providing legal support for potential claims.
- Firm Background: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, which further enhances investor confidence in the ongoing investigation.
See More
Faruqi & Faruqi Investigates Investor Losses in Beta Bionics
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Beta Bionics, aiming to provide legal support for investors who have suffered significant losses, indicating possible legal liabilities for the company.
- Investor Rights Protection: The firm encourages investors who have incurred losses in Beta Bionics stock or options to contact partner Josh Wilson directly, demonstrating its commitment to safeguarding investor legal rights.
- Reputation Impact: As a national securities law firm founded in 1995 that has recovered hundreds of millions for investors, this investigation could affect Beta Bionics' market reputation and future financing capabilities.
- Legal Consultation Channels: Investors can reach out to Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information on their legal rights, highlighting the firm's emphasis on client service.
See More
Beta Bionics Under Investigation Amid Stock Plunge
- Investor Investigation: Pomerantz LLP is investigating on behalf of Beta Bionics investors regarding potential securities fraud or other unlawful business practices, highlighting serious concerns about the company's governance and transparency.
- Declining Financial Performance: Beta Bionics reported a 36% year-over-year increase in new patient starts for Q4 2026, significantly lower than the 68% increase in the previous quarter, indicating challenges in market expansion.
- Stock Price Plunge: Following the earnings report, Beta Bionics' stock price fell by $11.85, or 37.03%, closing at $20.15 per share on January 9, 2026, severely impacting investor confidence.
- Legal Context: Pomerantz LLP, a renowned securities class action law firm with over 85 years of experience, focuses on advocating for victims of securities fraud, suggesting that this case may lead to broader legal implications.
See More
Beta Bionics Q4 2025 Earnings Call Highlights
- Significant User Growth: In 2025, Beta Bionics added nearly 20,000 new users, doubling its total user base to over 35,000, which lays a solid foundation for future market expansion and user adoption.
- Strong Financial Performance: The company reported $100.3 million in net sales for 2025, representing a 54% year-over-year growth, with Q4 sales reaching $32.1 million, up 57%, demonstrating robust competitive strength in the market.
- Margin Improvement: Q4 gross margin reached 59%, a 179 basis point increase year-over-year, reflecting the success in the pharmacy channel and its positive impact on overall profitability.
- Optimistic Future Outlook: Management expects revenue in 2026 to range between $130 million and $135 million, with plans to expand the sales force into 20 new territories, showcasing confidence in sustained growth and strategic positioning.
See More
Beta Bionics Reports Q4 2025 Financial Results
- Improved Financial Performance: Beta Bionics reported a narrowed net loss of $13.47 million in Q4 2025, down from $18.11 million the previous year, indicating positive progress in cost management and revenue growth, although the full-year net loss widened to $73.20 million, highlighting ongoing concerns about long-term profitability.
- Significant Revenue Growth: The company achieved a 57% year-over-year revenue increase in Q4, reaching $32.12 million, primarily driven by a 295% surge in Pharmacy Benefit Plan channel sales to $9.8 million, which lays a solid foundation for future market expansion and product acceptance.
- Optimistic Future Outlook: Beta Bionics anticipates total revenue for 2026 to be between $130 million and $135 million, reflecting confidence in new patient starts, with an estimated 36% to 38% expected to be reimbursed through the Pharmacy Benefit Plan, indicating strong market demand potential.
- R&D Progress on Track: The company recently completed the first-in-human Phase 2a feasibility trial for its bihormonal system in New Zealand and plans to initiate an additional feasibility trial in the first half of 2026, preparing for advanced-stage development and enhancing its competitive edge in diabetes treatment.
See More
